Travere Therapeutics (TVTX) Non-Current Deferred Tax Liability (2013 - 2017)

Travere Therapeutics has reported Non-Current Deferred Tax Liability for 5 years, with the latest figure at $1.2 million in Q2 2017.

• For the quarter ending Q2 2017, Non-Current Deferred Tax Liability fell 90.2% year-over-year to $1.2 million; the trailing twelve-month figure through Jun 2017 stood at $1.2 million (down 90.2% YoY), and the FY2016 full-year result was $6.4 million, down 73.59% from the prior year.
• Non-Current Deferred Tax Liability for Q2 2017 stood at $1.2 million, down from $4.4 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $39.9 million in Q1 2015, with the low at $141000.0 in Q4 2014.
• Historically, Non-Current Deferred Tax Liability has averaged $10.9 million across 5 years, with a median of $7.4 million in 2016.
• Annual changes were most pronounced in 2014 — Non-Current Deferred Tax Liability slumped 94.58% — and 2015, when it jumped 17153.9%.
• Travere Therapeutics' Non-Current Deferred Tax Liability stood at $2.6 million in 2013, then tumbled by 94.58% to $141000.0 in 2014, then jumped by 17153.9% to $24.3 million in 2015, then slumped by 73.59% to $6.4 million in 2016, then sank by 81.54% to $1.2 million in 2017.
• The last three Non-Current Deferred Tax Liability figures came in at $1.2 million (Q2 2017), $4.4 million (Q1 2017), and $6.4 million (Q4 2016), per Business Quant data.